The 10 Wall Street analysts covering Cybin, Inc. hold a median 12-month price target of $42 — +423.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Cybin, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (7): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Cybin, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on HELP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +423.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 July 2026 | Wells Fargo | Initiates | Overweight | $16 |
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | $95 → $70 |
| 9 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 13 Apr 2026 | TD Cowen | Initiates | Buy | — |
| 2 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Dec 2025 | Guggenheim | Maintains | Buy | — |
| 20 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 82% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HELP appears on the weeks it earns a place.
Helus Pharma has appointed Michael Halstead as its new Chief Executive Officer. Halstead previously served as President of Intra-Cellular Therapies, a company that was later acquired by Johnson & Johnson.
Why it matters — The appointment of a CEO with experience scaling a company that was acquired by a major pharmaceutical firm could signal strategic leadership changes at Helus Pharma.
The 10 Wall Street analysts covering Cybin, Inc. have a median 12-month price target of $42, with estimates ranging from $8.01 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Cybin, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cybin, Inc. 29 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Cybin, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +423.1% from the last close, and Ticker Nerd's factor model ranks Cybin, Inc. 29 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cybin, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HELP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.01 to $70 over the next 12 months.
Cybin, Inc. returned +6.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Cybin Inc. is a clinical-stage neuropsychiatry company dedicated to developing psychedelic-based therapeutics to address unmet needs in mental health treatment.
The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Helus Pharma Appoints Michael Halstead as Chief Executive Officer". Helus Pharma has appointed Michael Halstead as its new Chief Executive Officer. Halstead previously served as President of Intra-Cellular Therapies, a company that was later acquired by Johnson & Johnson.
Cybin Inc. is a clinical-stage neuropsychiatry company dedicated to developing psychedelic-based therapeutics to address unmet needs in mental health treatment. Its lead candidate, CYB003, a proprietary deuterated psilocybin analog, is advancing in phase 3 clinical trials for major depressive disorder, including the multinational EMBRACE study approved in Australia and Europe. CYB004, a deuterated DMT molecule, is in phase 2 trials for generalized anxiety disorder, with enrollment recently completed. The pipeline also features investigational compounds like SPL028, an injectable deuterated DMT that completed phase 1 trials, SPL026 for MDD, and CYB005, a phenethylamine derivative in preclinical stages targeting neuroinflammation and central nervous system disorders. Headquartered in Toronto, Ontario, with approximately 50 employees, Cybin Inc. collaborates with partners such as TMS Neurohealth Centers, Kernel, and Segal Trials to advance its research. Founded in 2016 and led by CEO Eric So, the company plays a pioneering role in the emerging field of psychedelic medicine within the biopharmaceutical sector, focusing on innovative solutions for conditions like depression and anxiety.
CEO Mr. Eric So L.L.B. · 100 employees · Canada · https://www.helus.com